FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $344,000 | -38.5% | 4,175 | -32.1% | 0.00% | 0.0% |
| Q4 2020 | $559,000 | +107.8% | 6,146 | -8.7% | 0.00% | 0.0% |
| Q3 2020 | $269,000 | +1.1% | 6,734 | -14.9% | 0.00% | 0.0% |
| Q2 2020 | $266,000 | +88.7% | 7,917 | -27.9% | 0.00% | 0.0% |
| Q4 2018 | $141,000 | +27.0% | 10,977 | -60.8% | 0.00% | 0.0% |
| Q3 2017 | $111,000 | +22.0% | 28,000 | 0.0% | 0.00% | – |
| Q2 2017 | $91,000 | -13.3% | 28,000 | +21.7% | 0.00% | -100.0% |
| Q1 2017 | $105,000 | +144.2% | 23,000 | +35.3% | 0.00% | – |
| Q4 2016 | $43,000 | -18.9% | 17,000 | 0.0% | 0.00% | – |
| Q3 2016 | $53,000 | +82.8% | 17,000 | 0.0% | 0.00% | – |
| Q2 2016 | $29,000 | -6.5% | 17,000 | 0.0% | 0.00% | – |
| Q1 2016 | $31,000 | +29.2% | 17,000 | +142.9% | 0.00% | – |
| Q4 2015 | $24,000 | -11.1% | 7,000 | +40.0% | 0.00% | – |
| Q3 2015 | $27,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |